Thermo Fisher Scientific Inc. (TMO)
NYSE · Healthcare · Diagnostics & Research
$676.76+3.35%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $250B
- P/E (trailing)
- 36.4
- Forward P/E
- 24.6
- Dividend yield
- 0.3%
- 52-week range
- $435.27 – $683.63
- 52-week change
- +21.45%
- EPS (trailing)
- $18.58
- Analyst rating
- 1.5 Strong buy
- Next earnings
- Oct 21, 2026
Fiscal year to Dec 2025
- Revenue
- $44.6B (+3.91%)
- Net income
- $6.7B
- Operating margin
- 17.4%
- Diluted EPS
- $17.74
- Free cash flow
- $6.3B
From the company’s annual report on SEC EDGAR.
About Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories.
Headquarters: Waltham, United States · 125,000 employees · thermofisher.com